Senseonics completes acquisition of Eversense CGM commercial assets in four European markets

Filed June 8, 2026 · Period ending June 1, 2026 · ~1 min read

Key Changes

• high

  Senseonics closed on acquiring Ascensia's commercial Eversense continuous glucose monitoring assets in Germany, Spain, Sweden, and Italy, with transactions effective June 1, 2026. The company now directly controls commercial operations for its flagship product in these key European markets.

  Item 2.01 view on EDGAR →
• high

  The acquisition includes all rights, title, and interest in commercial Eversense CGM activities across the four countries, along with associated liabilities and obligations. This follows the master agreement signed December 31, 2025, and local agreements from March 12, 2026.

  Item 2.01 view on EDGAR →